InterPAD - DETAILS

bleomycin, Bleomicin, Bleocin, Bleomycine, Bleomycinum, bleomycin a2, Bleomycine [INN-French], Bleomycinum [INN-Latin], Bleomicina [INN-Spanish], 11056-06-7, CCRIS 2754, HSDB 3208, NDC 0015-3010, UNII-40S1VHN69B, Bleo, NSC 125066, Bleomycin sulfate, Bleomicina, 40S1VHN69B, Bleomycine (INN-French), Bleomycinum (INN-Latin), Bleomicina (INN-Spanish), BLM, Bleomycin [INN], Bleomycin sulphate, Bleomycin [INN:BAN], NSC-125066, NSC125066, BLEOMYCIN (IARC), BLEOMYCINS (IARC), DTXSID1030862, SCHEMBL21090952, OYVAGSVQBOHSSS-WXFSZRTFSA-O, LMPK14000006, DB00290, MIXTURE OF CYTOTOXIC GLYCOPEPTIDES PRODUCED BY THE GROWTH OF STREPTOMYCES VERTICILLUS

No.	Title	Href
1	Effect-enhancing and toxicity-reducing activity of usnic acid in ascitic tumor-bearing mice treated with bleomycin. Int Immunopharmacol. 2017 May;46:146-155. doi: 10.1016/j.intimp.2017.03.004.	`Click`

No.

Title

Href

Effect-enhancing and toxicity-reducing activity of usnic acid in ascitic tumor-bearing mice treated with bleomycin. Int Immunopharmacol. 2017 May;46:146-155. doi: 10.1016/j.intimp.2017.03.004.

Click

Name	Bleomycin
PubChem CID	5360373
Molecular Weight	1415.6g/mol
Synonyms	bleomycin, Bleomicin, Bleocin, Bleomycine, Bleomycinum, bleomycin a2, Bleomycine [INN-French], Bleomycinum [INN-Latin], Bleomicina [INN-Spanish], 11056-06-7, CCRIS 2754, HSDB 3208, NDC 0015-3010, UNII-40S1VHN69B, Bleo, NSC 125066, Bleomycin sulfate, Bleomicina, 40S1VHN69B, Bleomycine (INN-French), Bleomycinum (INN-Latin), Bleomicina (INN-Spanish), BLM, Bleomycin [INN], Bleomycin sulphate, Bleomycin [INN:BAN], NSC-125066, NSC125066, BLEOMYCIN (IARC), BLEOMYCINS (IARC), DTXSID1030862, SCHEMBL21090952, OYVAGSVQBOHSSS-WXFSZRTFSA-O, LMPK14000006, DB00290, MIXTURE OF CYTOTOXIC GLYCOPEPTIDES PRODUCED BY THE GROWTH OF STREPTOMYCES VERTICILLUS
Drug Type	Small molecule
Formula	C₅₅H₈₄N₁₇O₂₁S₃+
SMILES	CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O
InChI	1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1
InChIKey	OYVAGSVQBOHSSS-WXFSZRTFSA-O
CAS Number	11056-06-7
TTD ID	D06UVD
Drug Bank ID	DB00290
KEGG ID	C06854
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Usnic acid, Bleomycin
Partner Name	Usnic acid
Disease Info	[ICD-11: 2F94]	Ascitic tumor		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G0/G1 phase
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP8	hsa841
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	CCNE1	hsa898
	Up-regulation	Expression	CDKN1A	hsa1026
	Up-regulation	Expression	IL1B	hsa3553
	Up-regulation	Expression	IL6	hsa3569
	Up-regulation	Expression	PHEX	hsa5251
	Down-regulation	Expression	SMAD2	hsa4087
	Up-regulation	Expression	SMAD3	hsa4088
	Up-regulation	Expression	SMAD7	hsa4092
	Down-regulation	Expression	SOD1	hsa6647
	Up-regulation	Expression	TGFB1	hsa7040
	Up-regulation	Expression	TNF	hsa7124
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	H22	Hepatocellular carcinoma	Mus musculus (Mouse)	CVCL_H613
In Vivo Model	Mice in Model, BLM, UA and UA + BLM groups were inoculated with H22 cells (0.2 mL, 2×10⁶ cells/mouse, i.p.) to establish malignant ascites tumor-bearing mouse model.
Result	Effect-enhancing and toxicity-reducing activity of usnic acid in ascitic tumor-bearing mice treated with bleomycin